Literature DB >> 12825193

Sendai virus vectors as an emerging negative-strand RNA viral vector system.

Michael Bitzer1, Sorin Armeanu, Ulrich M Lauer, Wolfgang J Neubert.   

Abstract

The power to manipulate the genome of negative-strand RNA viruses, including the insertion of additional non-viral genes, has led to the development of a new class of viral vectors for gene transfer approaches. The murine parainfluenza virus type I, or Sendai virus (SeV), has emerged as a prototype virus of this vector group, being employed in numerous in vitro as well as animal studies over the last few years. Extraordinary features of SeV are the remarkably brief contact time that is necessary for cellular uptake, a strong but adjustable expression of foreign genes, efficient infection in the respiratory tract despite a mucus layer, transduction of target cells being independent of the cell cycle, and an exclusively cytoplasmic replication cycle without any risk of chromosomal integration. In this review we describe the current knowledge of Sendai virus vector (SeVV) development as well as the results of first-generation vector applications under both in vitro and in vivo conditions. So far, Sendai virus vectors have been identified to be a highly efficient transduction tool for a broad range of different tissues and applications. Future directions in vector design and development are discussed. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825193     DOI: 10.1002/jgm.426

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  26 in total

1.  Optimizing vector application for gene transfer into human hepatoblastoma cells.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Heitmann; Peter Ruck; Guido Seitz; Johannes T Wessels; Marie-Luise Lemken; Ulrich M Lauer; Jörg Fuchs; Michael Bitzer
Journal:  Pediatr Surg Int       Date:  2006-07-29       Impact factor: 1.827

2.  In vitro gene targeting in human hepatoblastoma.

Authors:  Steven W Warmann; Sorin Armeanu; Heike Frank; Heike Buck; Florian Graepler; Marie-Luise Lemken; Heike Heitmann; Guido Seitz; Ulrich M Lauer; Michael Bitzer; Jörg Fuchs
Journal:  Pediatr Surg Int       Date:  2006-01       Impact factor: 1.827

3.  Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice.

Authors:  Hiroki Takeuchi; Keiko Imamura; Bin Ji; Kayoko Tsukita; Takako Enami; Keizo Takao; Tsuyoshi Miyakawa; Masato Hasegawa; Naruhiko Sahara; Nobuhisa Iwata; Makoto Inoue; Hideo Hara; Takeshi Tabira; Maiko Ono; John Q Trojanowski; Virginia M-Y Lee; Ryosuke Takahashi; Tetsuya Suhara; Makoto Higuchi; Haruhisa Inoue
Journal:  NPJ Vaccines       Date:  2020-03-25       Impact factor: 7.344

Review 4.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

Review 5.  An Insight into DNA-free Reprogramming Approaches to Generate Integration-free Induced Pluripotent Stem Cells for Prospective Biomedical Applications.

Authors:  Manash P Borgohain; Krishna Kumar Haridhasapavalan; Chandrima Dey; Poulomi Adhikari; Rajkumar P Thummer
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

6.  Measles vector as a multigene delivery platform facilitating iPSC reprogramming.

Authors:  Qi Wang; Alanna Vossen; Yasuhiro Ikeda; Patricia Devaux
Journal:  Gene Ther       Date:  2019-02-04       Impact factor: 5.250

Review 7.  Vectorology and factor delivery in induced pluripotent stem cell reprogramming.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-04-16       Impact factor: 3.272

8.  A "top-down" approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery.

Authors:  Yuhang Jiang; Alice Gaudin; Junwei Zhang; Tushar Agarwal; Eric Song; Amy C Kauffman; Gregory T Tietjen; Yongheng Wang; Zhaozhong Jiang; Christopher J Cheng; W Mark Saltzman
Journal:  Biomaterials       Date:  2018-05-25       Impact factor: 12.479

9.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

Review 10.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.